Skip to main content
. 2016 Aug 18;7(39):63549–63560. doi: 10.18632/oncotarget.11363

Figure 1. Selective binding of ALOS4 to αvβ3.

Figure 1

A. ALOS4-FITC binding in wells pre-coated with integrin αvβ3. ALOS4 binding to αvβ3: Kd = 0.192±0.038 μM. B. ALOS4-FITC binding in wells coated with collagen or BSA. C. Binding of random, FTIC-labeled cyclic nonapeptide controls (DPDFP and DSLFP) in wells pre-coated with integrin αvβ3. D. Competitive homologous binding of ALOS4 to αvβ3 integrin. 10 μM of ALOS4-FITC peptide was incubated with different concentrations of unlabeled ALOS4 on wells pre-coated with αvβ3. Kd = 2.55±1.22 μM. Data are expressed as percent reduction of maximal fluorescence signal.